



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com <http://www.wjgnet.com>

Name of Journal: *World Journal of Gastrointestinal Pharmacology and Therapeutics*

ESPS Manuscript NO: 20838

Manuscript Type: REVIEW

RESPONSE TO REVIEWERS

Thanks to all reviewers for their comments. Major revisions are highlighted in yellow.

Reviewer A

1- Specific considerations Abstract: I suggest that completion of the abstract need to be more specific and representative of the conclusions contained in the article text.

Done. Abstract has been modified as suggested.

2- Text: on the 2nd line of the 3rd paragraph of page 6, it would be desirable for the authors to give more current data (if any) of the related mortality with hepatitis C.

Additional data on mortality has been described later in this article showing the reduction in mortality after achieving a sustained virological response (SVR)

3- It would also be attractive to the authors could explain or speculate why that "...anti-HCV seropositive Individuals with detectable serum HCV RNA have an increased risk of dying from all causes, whereas the risk for anti-HCV seropositives with negative HCV RNA is similar of seronegative HCV Individuals.

Done. Other HCV -associated comorbidities with HCV seropositives that are cryoglobulinemia, lymphoma as well as skin rash, and renal manifestations.

4-: The realization that "...individuals with chronic hepatitis C having an active infection manifested by HCV-RNA positivity should benefit from antiviral treatment to reduce both their overall mortality as well as hepatic disease mortality risk. "(Page 7, last sentence) and that "... rather early than later therapy of HCV infected individuals would be even more efficacious than waiting particularly if it includes all cases from F0-F4 hepatic disease." (1st paragraph, page 11), I believe that these information deserve highlight the conclusions, as they are important information for the readers. The same applies to the claim that "...that treatment regimens without any restrictions would result in a substantial reduction in health care costs and simultaneously reduce the number of infected Individuals who are infected can infect others."

Done

5- In the 1st line of the 3rd paragraph of page 10, the reference to authors should follow "et al." instead of being placed at the end of the sentence.

Done

6- In 2nd line of page 13, I think there is missed a word after "... is much more (what?) Than an hepatic disease ... "

Thank you. Actually, no word is missing. It meant the manifestations go beyond (much more) the liver disease. The sentence was rewritten to facilitate understanding.

Reviewer B

Reviewer: This manuscript is informative and well written

Response: Thank you

Reviewer C

1-The format should be changed in accordance with the journal's instructions.

Done

2- Minor errors should be revised. *Page 9: In contrast, the newly developed direct acting (DNA) → DAA? *Page 11: ...more convenient to administor (→ administer?) and were assosciated (→ associated?) with fewer side effects * 'IFN-based therapies' and 'IFN based therapies' were used in the text. Please unify the style.

Sorry for that. Thank you. Done

3- Abbreviation should be defined in the abstract and on first mention in the text.

Done